Brolucizumab and Platelet Activation and Reactivity.

Area of Science:

• Ophthalmology
• Hematology
• Pharmacology

Background:

• Brolucizumab is an anti-VEGF agent used for retinal diseases.
• Safety concerns, including platelet interaction, are important for anti-VEGF therapies.
• Understanding brolucizumab's effect on platelets is crucial for managing retinal vasculitis and occlusion.

Purpose of the Study:

• To investigate the potential interaction of brolucizumab with human platelets.
• To assess the effects of brolucizumab on platelet activation and reactivity.
• To evaluate the safety of brolucizumab concerning platelet function.

Main Methods:

• Platelets from healthy volunteers were exposed to varying concentrations of brolucizumab.
• Platelet activation markers (GPIIb/IIIa, P-selectin) were measured using multispectral imaging flow cytometry.
• Brolucizumab-platelet interaction was studied using FITC-labeled antibodies and cross-pretreatment experiments.

Main Results:

• Brolucizumab did not significantly alter platelet activation markers (CD62P, GPIIb/IIa) at tested concentrations.
• No significant platelet activation or interaction was observed with brolucizumab or anti-brolucizumab antibodies.
• Brolucizumab-FITC showed lower binding compared to bevacizumab-FITC, with both being downregulated by pretreatment.

Conclusions:

• Brolucizumab does not appear to directly affect platelet activation or reactivity.
• The study found no evidence of direct platelet interaction with brolucizumab.
• Further investigation may be needed to explore potential platelet uptake of brolucizumab.